Wednesday, July 15, 2026
1:00PM – 2:00PM ET
Location: Virtual
Project Overview One Pager Panelist Biographies
The use of OS as a safety endpoint is receiving increasing attention in oncology drug development, and there is a growing need for evidence-based approaches to guide both trial design and interpretation of these data. Friends of Cancer Research (Friends) hosted a webinar to present a simulation-informed framework to support interpretation of interim overall survival (OS) results, with a focus on assessing potential treatment-related harm. Interim OS analyses are often based on immature data yet can influence important clinical and regulatory decisions.
A panel of experts discussed practical considerations for applying this framework in the design and interpretation of oncology trials and the implications for regulatory decision-making.
AGENDA
Welcome and Opening Remarks
- Mark Stewart, Friends of Cancer Research
Project Overview and Key Findings (Presentation Slides)
- Névine Zariffa, NMD Group, LLC
Panel Discussion
- Briggs Morrison, Crossbow Therapeutics – Moderator
- Andrew Mills, MMS Holdings Ltd
- Kiran Patel, Johnson & Johnson Innovative Medicine
- Lisa Rodriguez, GSK
- Shu Wang, FDA
- Névine Zariffa, NMD Group, LLC
Closing Remarks
- Mark Stewart, Friends of Cancer Research